Plain-English translation of NCT04851119 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new medication called to see if it can help treat solid tumors—including bone cancers, liver cancers, kidney tumors, and certain lymphomas—that have come back or stopped responding to previous treatments. works by targeting a specific pathway in cancer cells. The study will first find the right dose and then test how well the medication works against different tumor types.
Children and young adults with cancers that return or resist standard chemotherapy have very limited treatment options. This medication targets a new pathway in cancer cells that hasn't been tested much in young patients yet, and researchers hope it may work for tumors that other treatments have failed to control.
You likely qualify if…
You likely don't qualify if…
You would receive the medication through an IV (intravenous line) once a week for three weeks, then take one week off—this pattern repeats every 28 days for up to 24 months or until the cancer progresses. You'll have regular doctor visits, imaging scans (X-rays and bone density scans), and blood tests to monitor how the medication is working and watch for side effects. The trial first tests different doses to find the safest one, then uses that dose in a larger group to see if the medication actually shrinks tumors.
AI-generated summary from trial data · Sep 1, 2026 · Not medical advice
United States